For the quarter ending 2026-03-31, BHIC had $483,080 increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income (loss) | -229,907 | -233,630 | -8,782 | 884,502 |
| Lease cost, net of repayments | -13,122 | 61,236 | - | - |
| Accounts receivable | -320,979 | 336,045 | -326,801 | 289,728 |
| Inventory | 537,992 | -421,152 | 508,981 | 190,200 |
| Deferred revenue | -59,841 | 25,599 | -137,668 | 224,330 |
| Deferred tax | - | 2,069 | - | - |
| Accrued expenses | 14,824 | 1,271 | -17,814 | 18,507 |
| Accounts payable | - | -3,891 | -6,471 | 8,410 |
| Deposits | - | 4,400 | - | - |
| Accounts payable | 513 | 79,030 | - | - |
| Prepaid expenses | 73,805 | -13,523 | -12,470 | 42,502 |
| Net cash provided by (used in) operating activities | -552,107 | -100,696 | -340,445 | 613,319 |
| Purchase of intangible assets | 0 | 10,786 | 0 | 46,064 |
| Advances from related parties | 748,120 | 623,984 | 1,030,461 | 1,391,635 |
| Repayment to related parties | 150,000 | 990,000 | 850,000 | 1,322,000 |
| Proceeds from the sale of common stock | 437,067 | 0 | 0 | 0 |
| Net cash provided by financing activities | 1,035,187 | -366,016 | 180,461 | 69,635 |
| Net increase in cash | 483,080 | -477,498 | -159,984 | 636,890 |
| Cash at beginning of period | 661,925 | 1,139,423 | 662,517 | - |
| Cash at end of period | 1,145,005 | 661,925 | 1,139,423 | - |
BioScience Health Innovations, Inc. (BHIC)
BioScience Health Innovations, Inc. (BHIC)